Adverum Biotechnologies Statistics
Share Statistics
Adverum Biotechnologies has 20.89M
shares outstanding. The number of shares has increased by 0.22%
in one year.
| Shares Outstanding | 20.89M |
| Shares Change (YoY) | 0.22% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 76.04% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 479 |
| FTD / Avg. Volume | 0.19% |
Short Selling Information
The latest short interest is 1.43M, so 6.82% of the outstanding
shares have been sold short.
| Short Interest | 1.43M |
| Short % of Shares Out | 6.82% |
| Short % of Float | 6.87% |
| Short Ratio (days to cover) | 8.39 |
Valuation Ratios
The PE ratio is -0.71 and the forward
PE ratio is -0.79.
Adverum Biotechnologies's PEG ratio is
0.02.
| PE Ratio | -0.71 |
| Forward PE | -0.79 |
| PS Ratio | 92.38 |
| Forward PS | 3.1 |
| PB Ratio | 1.31 |
| P/FCF Ratio | -0.99 |
| PEG Ratio | 0.02 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Adverum Biotechnologies.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.73,
with a Debt / Equity ratio of 1.3.
| Current Ratio | 5.73 |
| Quick Ratio | 5.73 |
| Debt / Equity | 1.3 |
| Debt / EBITDA | -0.68 |
| Debt / FCF | -0.99 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $6,451.61 |
| Profits Per Employee | $-844,690.32 |
| Employee Count | 155 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -66.7% in the
last 52 weeks. The beta is 1.09, so Adverum Biotechnologies's
price volatility has been higher than the market average.
| Beta | 1.09 |
| 52-Week Price Change | -66.7% |
| 50-Day Moving Average | 4.04 |
| 200-Day Moving Average | 5.82 |
| Relative Strength Index (RSI) | 46.2 |
| Average Volume (20 Days) | 249,001 |
Income Statement
In the last 12 months, Adverum Biotechnologies had revenue of 1M
and earned -130.93M
in profits. Earnings per share was -6.62.
| Revenue | 1M |
| Gross Profit | -2.65M |
| Operating Income | -139.16M |
| Net Income | -130.93M |
| EBITDA | -135.51M |
| EBIT | -139.16M |
| Earnings Per Share (EPS) | -6.62 |
Full Income StatementBalance Sheet
The company has 60.65M in cash and 91.7M in
debt, giving a net cash position of -31.05M.
| Cash & Cash Equivalents | 60.65M |
| Total Debt | 91.7M |
| Net Cash | -31.05M |
| Retained Earnings | -1.07B |
| Total Assets | 179.84M |
| Working Capital | 108.4M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -92.46M
and capital expenditures -388K, giving a free cash flow of -92.85M.
| Operating Cash Flow | -92.46M |
| Capital Expenditures | -388K |
| Free Cash Flow | -92.85M |
| FCF Per Share | -4.69 |
Full Cash Flow StatementMargins
Gross margin is -265.3%, with operating and profit margins of -13915.9% and -13092.7%.
| Gross Margin | -265.3% |
| Operating Margin | -13915.9% |
| Pretax Margin | -13092.7% |
| Profit Margin | -13092.7% |
| EBITDA Margin | -13550.6% |
| EBIT Margin | -13915.9% |
| FCF Margin | -9285% |
